MAPT and Alzheimer disease: The confirmatory Phase III trial, TRAILBLAZER-ALZ 2 (NCT04437511), enrolled approximately 1736 patients with early AD, including both individuals with intermediate tau levels and those with high tau pathology (around 68% of participants had low or medium tau and 32% had high tau, stratified to ensure representation of both subgroups) [87].